<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144687</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 39110-209</org_study_id>
    <nct_id>NCT03144687</nct_id>
  </id_info>
  <brief_title>A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis</brief_title>
  <official_title>An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with
      low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in spleen volume reduction</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>Measured by magnetic resonance imaging (MRI); computed tomography (CT) scan in subjects who are not candidates for MRI or when MRI is not readily available.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage change in spleen volume reduction</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>Measured by magnetic resonance imaging (MRI); computed tomography (CT) scan in subjects who are not candidates for MRI or when MRI is not readily available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of itacitinib alone through assessment of frequency, severity, and duration of adverse events (AEs)</measure>
    <time_frame>Baseline through 30-35 days after last dose of itacitinib, up to 8 months per subject.</time_frame>
    <description>An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a subject provides informed consent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of itacitinib in combination with ruxolitinib through assessment of frequency, severity, and duration of AEs</measure>
    <time_frame>Baseline through 30-35 days after last dose of itacitinib, up to 8 months per subject</time_frame>
    <description>An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a subject provides informed consent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spleen volume reduction</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Measured by MRI (CT scan in subjects who are not candidates for MRI or when MRI is not readily available).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in spleen volume reduction</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Measured by MRI (CT scan in subjects who are not candidates for MRI or when MRI is not readily available).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spleen length reduction</measure>
    <time_frame>Baseline through Week 12 and Week 24</time_frame>
    <description>Measured by palpation (in centimeters using a soft ruler).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in spleen length reduction</measure>
    <time_frame>Baseline through Week 12 and Week 24</time_frame>
    <description>Measured by palpation (in centimeters using a soft ruler).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Symptom Score</measure>
    <time_frame>Baseline through Week 12 and Week 24</time_frame>
    <description>Measured by the Myelofibrosis Symptom Assessment Form v2.0 and by the Myeloproliferative Neoplasm-Symptom Assessment Form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Total Symptom Score</measure>
    <time_frame>Baseline through Week 12 and Week 24</time_frame>
    <description>Measured by the Myelofibrosis Symptom Assessment Form v2.0 and by the Myeloproliferative Neoplasm-Symptom Assessment Form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Impression of Change (PGIC) score</measure>
    <time_frame>Protocol-defined timepoints from Week 4 through end of treatment, up to approximately 7 months per subject.</time_frame>
    <description>Subjects complete a 1-question assessment form of their myelofibrosis symptoms since the start of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>MPN (Myeloproliferative Neoplasms)</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itacitinib plus ruxolitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itacitinib alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>Itacitinib self-administered orally once daily at the protocol-defined dose.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib self-administered orally at the stable dose of &lt; 20 mg daily established before entering the study.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <other_name>INCB018424</other_name>
    <other_name>Jakafi</other_name>
    <other_name>Jakavi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort A only

        • Receiving ruxolitinib dose of less than 20 mg daily with no dose increase or no dose
        modification in the last 8 weeks before screening visit.

        Cohort B only

        • Must have had initial reduction in spleen on ruxolitinib treatment:

          -  Followed by documented evidence of progression in spleen length or volume OR

          -  Discontinued ruxolitinib for hematologic toxicities, after the initial reduction in
             spleen length or volume.

        All subjects

          -  Confirmed diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or
             post-essential thrombocythemia myelofibrosis according to revised World Health
             Organization 2016 criteria.

          -  Must have palpable spleen of ≥ 5 cm below the left subcostal margin on physical
             examination at the screening visit.

          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2.

          -  Screening bone marrow biopsy specimen available or willingness to undergo a bone
             marrow biopsy at screening/baseline; willingness to undergo bone marrow biopsy at Week
             24.

          -  Life expectancy of at least 24 weeks.

          -  Willingness to avoid pregnancy or fathering children

        Exclusion Criteria:

          -  Lack of recovery from all toxicities from previous therapy (except ruxolitinib) to
             Grade 1 or better.

          -  Previous treatment with itacitinib or JAK1 inhibitors (JAK1/JAK2 inhibitor ruxolitinib
             is permitted).

          -  Inability to swallow food or any condition of the upper gastrointestinal tract that
             precludes administration of oral medications.

          -  Recent history of inadequate bone marrow reserve as demonstrated by protocol-defined
             criteria.

          -  Inadequate liver function at screening and baseline visits as demonstrated by
             protocol-defined criteria.

          -  Inadequate renal function at screening and baseline visits as demonstrated by
             protocol-defined criteria.

          -  Active bacterial, fungal, parasitic, or viral infection that requires therapy.

          -  Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of
             reactivation: HBV DNA and HCV RNA must be undetectable. Subjects cannot be positive
             for hepatitis B surface antigen or anti-hepatitis B core antibodies. Subjects who have
             positive anti-HBs as the only evidence of prior exposure may participate in the study
             provided that there is both 1) no known history of HBV infection and 2) verified
             receipt of hepatitis B vaccine.

          -  Known human immunodeficiency virus infection.

          -  Clinically significant or uncontrolled cardiac disease.

          -  Active invasive malignancy over the previous 2 years except treated basal or squamous
             carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix,
             and completely resected papillary thyroid and follicular thyroid cancers. Subjects
             with malignancies with indolent behavior such as prostate cancer treated with
             radiation or surgery may be enrolled as long as they have a reasonable expectation to
             have been cured with the treatment modality received.

          -  Splenic irradiation within 6 months before receiving the first dose of itacitinib.

          -  Use of any prohibited concomitant medications.

          -  Active alcohol or drug addiction that would interfere with their ability to comply
             with the study requirements.

          -  Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5
             half-lives (whichever is longer) before the first dose of itacitinib or anticipated
             during the study.

          -  Use of concomitant treatment of fluconazole at a dose &gt; 200 mg (for ruxolitinib
             subjects treated in Cohort A only).

          -  Inadequate recovery from toxicity and/or complications from a major surgery before
             starting therapy.

          -  Currently breastfeeding or pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Pande, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-256-1664</phone>
    </contact>
    <investigator>
      <last_name>Kasra Karamlou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-456-5408</phone>
    </contact>
    <investigator>
      <last_name>Angela Fleischman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anschutz Cancer Pavilion - University Of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-848-2587</phone>
    </contact>
    <investigator>
      <last_name>Brandon McMahon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-852-2996</phone>
    </contact>
    <investigator>
      <last_name>Richard Frank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-687-0116</phone>
    </contact>
    <investigator>
      <last_name>Craig Kessler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Research Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>260-425-6831</phone>
    </contact>
    <investigator>
      <last_name>Robert Manges</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Maryland - Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-328-6635</phone>
    </contact>
    <investigator>
      <last_name>Duong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>734-936-3879</phone>
    </contact>
    <investigator>
      <last_name>Moshe Talpaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-576-9758</phone>
    </contact>
    <investigator>
      <last_name>Jay Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>248-849-5332</phone>
    </contact>
    <investigator>
      <last_name>Howard Terebelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>505-925-0379</phone>
    </contact>
    <investigator>
      <last_name>Arana Yi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Centers</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-746-2389</phone>
    </contact>
    <investigator>
      <last_name>Ellen Ritchie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>914-493-8375</phone>
    </contact>
    <investigator>
      <last_name>Karen Seiter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-681-4769</phone>
    </contact>
    <investigator>
      <last_name>Murat Arcasoy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-444-9464</phone>
    </contact>
    <investigator>
      <last_name>Aaron Gerds, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-4631</phone>
    </contact>
    <investigator>
      <last_name>Jeff Sharman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-595-5680</phone>
    </contact>
    <investigator>
      <last_name>Roger Lyons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>903-579-9800</phone>
    </contact>
    <investigator>
      <last_name>Habte Yimer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>434-982-3927</phone>
    </contact>
    <investigator>
      <last_name>Michael Keng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelofibrosis</keyword>
  <keyword>Janus kinase (JAK) inhibitor</keyword>
  <keyword>itacitinib</keyword>
  <keyword>ruxolitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

